Title
|
|
|
|
Early treatment versus expectative management of patent ductus arteriosus in preterm infants : a multicentre, randomised, non-inferiority trial in Europe (BeNeDuctus trial)
| |
Author
|
|
|
|
| |
Abstract
|
|
|
|
Background: Much controversy exists about the optimal management of a patent ductus arteriosus (FDA) in preterm infants, especially in those born at a gestational age (GA) less than 28 weeks. No causal relationship has been proven between a (haemodynamically significant) PDA and neonatal complications related to pulmonary hyperperfusion and/or systemic hypoperfusion. Although studies show conflicting results, a common understanding is that medical or surgical treatment of a FDA does not seem to reduce the risk of major neonatal morbidities and mortality. As the PDA might have closed spontaneously, treated children are potentially exposed to iatrogenic adverse effects. A conservative approach is gaining interest worldwide, although convincing evidence to support its use is lacking. Methods: This multicentre, randomised, non-inferiority trial is conducted in neonatal intensive care units. The study population consists of preterm infants (GA < 28 weeks) with an echocardiographic-confirmed PDA with a transductal diameter > 1.5 mm. Early treatment (between 24 and 72 h postnatal age) with the cyclooxygenase inhibitor (COXi) ibuprofen (IBU) is compared with an expectative management (no intervention intended to close a PDA). The primary outcome is the composite of mortality, and/or necrotising enterocolitis (NEC) Bell stage >= IIa, and/or bronchopulmonary dysplasia (BPD) defined as the need for supplemental oxygen, all at a postmenstrual age (PMA) of 36 weeks. Secondary outcome parameters are short term sequelae of cardiovascular failure, comorbidity and adverse events assessed during hospitalization and long-term neurodevelopmental outcome assessed at a corrected age of 2 years. Consequences regarding health economics are evaluated by cost effectiveness analysis and budget impact analysis. Discussion: As a conservative approach is gaining interest, we investigate whether in preterm infants, born at a GA less than 28 weeks, with a PDA an expectative management is non-inferior to early treatment with IBU regarding to the composite outcome of mortality and/or NEC and/or BPD at a PMA of 36 weeks. |
| |
Language
|
|
|
|
English
| |
Source (journal)
|
|
|
|
BMC pediatrics. - London
| |
Publication
|
|
|
|
London
:
2018
| |
ISSN
|
|
|
|
1471-2431
| |
DOI
|
|
|
|
10.1186/S12887-018-1215-7
| |
Volume/pages
|
|
|
|
18
(2018)
, 14 p.
| |
Article Reference
|
|
|
|
262
| |
ISI
|
|
|
|
000440662700002
| |
Pubmed ID
|
|
|
|
30077184
| |
Medium
|
|
|
|
E-only publicatie
| |
Full text (Publisher's DOI)
|
|
|
|
| |
Full text (open access)
|
|
|
|
| |
|